Lisa Moris

KU Leuven

Papers

2

Total Citations

65

H-Index

2

About

Lisa Moris is a leading urologic oncologist whose research focuses on advancing treatment strategies for prostate cancer, particularly through minimally invasive and targeted approaches. Her major contributions center on evaluating the role of focal ablative therapy as a less morbid alternative to standard management for clinically localized prostate cancer, as detailed in her highly cited 2021 systematic review (52 citations). This work critically assessed the limitations of current evidence and provided essential recommendations for clinical practice and future research, shaping the conversation around organ-sparing treatments. Dr. Moris has also made significant strides in the surgical management of recurrent disease, notably through her 2019 study comparing robot-assisted versus open salvage lymph node dissection (13 citations). This research, which introduced a novel application of robotic technology for treating lymph node recurrence after radical prostatectomy, demonstrated the potential to delay palliative androgen deprivation therapy while improving peri-operative outcomes. Her work directly impacts clinical decision-making for patients facing complex prostate cancer recurrences, establishing her as a key voice in the evolution of urologic oncology toward more precise, patient-centered care.

Research Focus

Key Achievements

2
H-Index
2
Papers
65
Total Citations
33
Avg Citations/Paper
🏆 Most Cited Paper
A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research
52 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 42
🏛 Institutions: KU Leuven

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago